13:27 Fri 13 Oct 2017
The FDA will decide on Aerie’s Rhopressa eye drop this morning
Aerie Pharmaceuticals Inc (NASDAQ:AERI) is in the spotlight on Friday as the US Food and Drugs Administration is set to judge an application for its new eye drug.
Trading in the stock is on hold this morning as the FDA’s dermatologic and opthalmic drugs advisory committee will meet to review Aerie’s Rhopressa eye drop.
Rhopressa is intended to be a once daily application designed to reduce pressure on eyes resulting from glaucoma.
Price: 15.5 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE
MetalNRG PLC's (LON:MNRG) Rolf Gerritsen and Pierpaolo Rocco talk to Proactive London about the Sunswept Enterprise Limited transaction which is now complete. This follows confirmation from the Oil & Gas Authority that it does not oppose the change of control of Sunswept Enterprise...
VH Global Sustainable Energy Opportunities plc
Victory Hill does not 'follow the crowd', targeting the less...
Industry & services
Market Report: All eyes on Biden and Harris inauguration
Retail & consumer
Retail & consumer
Industry & services
